Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2019 Dec 26;105(11):2598–2607. doi: 10.3324/haematol.2019.231027

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright© 2020 Ferrata Storti Foundation

This article is distributed under the terms of the Creative Commons Attribution Noncommercial License (by-nc 4.0) which permits any noncommercial use, distribution, and reproduction in any medium, provided the original author(s) and source are credited.

PMC Copyright notice

Figure 2. — Outcomes of advanced stage chronic lymphocytic leukemia (CLL) cases according to subset classification. (A) Median time-to-first-treatment (TTFT) for the subset #1: 20.6 months, subset #2: 28.5 months, subset #4: 42.8 months, subset #8: 5.5 months, U-CLL: 17.8 months, M-CLL: 36.1 months. (B) Median timeto- next-treatment (TTNT) for the subset #1: 60.2 months, subset #2: 57.3 months, subset #4: not reached, subset #8: 43.7 months, U-CLL: 47.4 months, M-CLL: not reached. (C) Median progression-free survival (PFS) for subset #1: 41.7 months, subset #2: 33.3 months, subset #4: not reached, subset #8: 26.3 months, U-CLL: 26.5 months, M-CLL: 54.7 months. (D) Median overall survival (OS) for subset #1: 67.5 months, subset #2: not reached, subset #4: not reached, subset #8: 43.3 months, U-CLL: 78.9 months, M-CLL: not reached; Cum: cumulative.